Search Result

Results for "

VPAC2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	COX (1) GCGR (3) Interleukin Related (1) PACAP Receptor (6) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (6)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1160

Bay 55-9837	GCGR	Metabolic Disease
Bay 55-9837 is a potent and highly selective agonist of *VPAC2, with a K_d* of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes .

HY-133529

PA-8 2 Publications Verification	PACAP Receptor	Neurological Disease Inflammation/Immunology
PA-8 is a potent, selective and orally active PACAP type I (PAC1) receptor antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC₅₀ of 2 nM ^[2].

HY-P0176

PACAP (1-27), human, ovine, rat 3 Publications Verification PACAP 1-27	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat *VPAC1* and human *VPAC2*, respectively .

HY-P0176A

PACAP (1-27), human, ovine, rat TFA 3 Publications Verification PACAP 1-27 TFA	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat *VPAC1* and human *VPAC2*, respectively .

HY-P1160A

Bay 55-9837 TFA	GCGR	Metabolic Disease
Bay 55-9837 TFA is a potent and highly selective agonist of *VPAC2, with a K_d* of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes .

HY-172402

Vasoactive intestinal peptide	Interleukin Related COX	Infection
Vasoactive intestinal peptide is an agonist of *VPAC1/VPAC2* receptor (G-protein-coupled receptors). Vasoactive intestinal peptide reduces corneal perforation rate, bacterial load, and excessive neutrophil infiltration in Pseudomonas aeruginosa-induced keratitis models. Vasoactive intestinal peptide enhances anti-inflammatory mediators like IL-10 and TGF-β, inhibites pro-inflammatory factors such as IL-1β and TNF-α, and upregulates lipid mediator-related enzymes (SOCS3, COX-2, ALOX12) to promote inflammation resolution. Vasoactive intestinal peptide is promising for research of ocular infectious diseases .

HY-P10768

Ro 25-1553	PACAP Receptor	Neurological Disease
Ro 25-1553 is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .

HY-P991511

ALD1910	PACAP Receptor	Neurological Disease
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .

HY-P11288

ANT308	GCGR	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting *VIP-VPAC2* signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) ^[2].

HY-RS18849

Vipr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Vipr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vipr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vipr2 Mouse Pre-designed siRNA Set A Vipr2 Mouse Pre-designed siRNA Set A

HY-P4776

Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27)	PACAP Receptor	Metabolic Disease
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27), a vasoactive intestinal peptide (VIP), is a VIP₁ antagonist .

HY-RS15656

VIPR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
VIPR2 Human Pre-designed siRNA Set A contains three designed siRNAs for VIPR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VIPR2 Human Pre-designed siRNA Set A VIPR2 Human Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area

HY-P5111

Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr free acid	Peptides	Neurological Disease
Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr (free acid) is a high-affinity and selective VPAC2 receptor antagonist .

HY-P1160

Bay 55-9837	GCGR	Metabolic Disease
Bay 55-9837 is a potent and highly selective agonist of *VPAC2, with a K_d* of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes .

HY-P0176

PACAP (1-27), human, ovine, rat 3 Publications Verification PACAP 1-27	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat *VPAC1* and human *VPAC2*, respectively .

HY-P0176A

PACAP (1-27), human, ovine, rat TFA 3 Publications Verification PACAP 1-27 TFA	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat *VPAC1* and human *VPAC2*, respectively .

HY-P4776

Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27)	PACAP Receptor	Metabolic Disease
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27), a vasoactive intestinal peptide (VIP), is a VIP₁ antagonist .

HY-P1160A

Bay 55-9837 TFA	GCGR	Metabolic Disease
Bay 55-9837 TFA is a potent and highly selective agonist of *VPAC2, with a K_d* of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes .

HY-P10768

Ro 25-1553	PACAP Receptor	Neurological Disease
Ro 25-1553 is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .

HY-P11288

ANT308	GCGR	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting *VIP-VPAC2* signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) ^[2].

Cat. No.	Product Name	Target	Research Area

HY-P991511

ALD1910	PACAP Receptor	Neurological Disease
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .

Cat. No.	Compare	Product Name	Species	Source

HY-P76128

	VIPR2 Protein, Human (HEK293, Fc) Vasoactive intestinal polypeptide receptor 2; VIP-R-2; PACAP-R3; VPAC2; VIPR2	Human	HEK293
	VIPR2 protein, serving as a receptor for Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activating Peptide (PACAP-38 and -27), activates adenylyl cyclase and can also couple with phospholipase C. Its versatile signaling pathways emphasize its pivotal role in transducing signals from VIP and PACAP, participating in cellular processes regulated by cyclic AMP and phosphoinositide signaling cascades. VIPR2 Protein, Human (HEK293, Fc) is the recombinant human-derived VIPR2 protein, expressed by HEK293 , with C-mFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81526

	VPAC2 Antibody (YA1271) VIP2R; VIPR2; Vasoactive intestinal polypeptide receptor 2; VIP-R-2; Helodermin-preferring VIP receptor; Pituitary adenylate cyclase-activating polypeptide type III receptor (PACAP type III receptor; PACAP-R-3; PACAP-R3); VPAC2	IHC-P	Human
	VPAC2 Antibody (YA1271) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VPAC2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS18849

Vipr2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Vipr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vipr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS15656

VIPR2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
VIPR2 Human Pre-designed siRNA Set A contains three designed siRNAs for VIPR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.